RULE CATALOG

GIC Physician Quality Profiler (PQP)

VERSION: 1.1
DATE: NOVEMBER 24, 2014
CLASS.: CONFIDENTIAL, FOR INTERNAL USE ONLY
AUTHORS: MICHAEL GIBBONS, BOB NOLAN

Resolution Health, Inc. Proprietary Statement: This material constitutes proprietary and trade secret information of Resolution Health and shall not be disclosed to any third party, nor used by the recipient except under the terms and conditions prescribed by Resolution Health. This material is not to be copied or reproduced in any form, using any medium, without the prior written authorization of Resolution Health.

Disclaimer of Currency: Resolution Health documentation reflects the state of products, software, reports, and procedures as of the publication date. All information is subject to change without notice. Additional changes to products and systems occur as needed, but may not be documented until a later date.
# TABLE OF CONTENTS

Cancer Surveillance .................................................................................................................. 5
  Breast cancer history annual surveillance (NQF) (11923) .................................................. 5
  Prostate cancer annual cancer surveillance (NQF) (10220) ............................................. 5

Cardiac Measures: Atrial Fibrillation ...................................................................................... 6
  Atrial fibrillation and stroke risk on warfarin (NQF) (11941) ............................................. 6
  New Atrial Fibrillation: Thyroid Function Test (1972) ....................................................... 7
  Atrial fibrillation warfarin INR check (211) ...................................................................... 7

Cardiac Measures: Heart Failure ............................................................................................. 8
  Heart failure ACE-I or ARB use (NQF) (11931) ................................................................. 8
  Heart failure on beta blocker (NQF) (11933) .................................................................. 8
  CHF avoid DHP calcium channel blocker (175) ............................................................... 9

Cardiac Measures: Coronary Heart Disease .......................................................................... 9
  CHD post-MI on ACE inhibitor (NQF) (398) ...................................................................... 9
  CHD post-MI on beta blocker (157) ................................................................................ 10
  HEDIS CHD cholesterol management (3798) ................................................................. 11
  Bare metal stent antiplatelet within 30 days (2682) ......................................................... 11
  Drug-eluting stent antiplatelet 3 months (NQF) (4141) .................................................... 12
  HEDIS MI hospitalization beta blocker 6 months (383) .................................................... 13

Cardiac Measures: Hypertension ............................................................................................ 14
  HTN had creatinine test (11398) ..................................................................................... 14
  New hypertension glucose test (152) ............................................................................... 15
  New hypertension potassium test (153) .......................................................................... 15
  New hypertension lipid test (154) .................................................................................. 16
  Hypertension avoid SA DHP calcium channel blocker (174) ......................................... 16

Drug Safety Measures: .......................................................................................................... 17
  Amiodarone baseline thyroid test (NQF) (412) ................................................................. 17
  Amiodarone annual thyroid test (20442) ........................................................................... 17
  HEDIS ACEI or ARB annual potassium and creatinine (395) ........................................... 18
  HEDIS digoxin annual potassium and creatinine (377) ..................................................... 19
  HEDIS diuretics annual potassium and creatinine (394) .................................................... 19
  HEDIS anticonvulsants annual drug level (390) ............................................................... 20
  Clozapine white blood cell count (401) .......................................................................... 20
  Lithium annual creatinine test (NQF) (2427) ................................................................. 21
  Lithium annual thyroid function test (NQF) (2428) ......................................................... 21
Lithium annual drug level test (NQF) (2424) .............................................. 22
Benign prostatic hypertrophy avoid anticholinergic (423) ................................ 22
HEDIS elderly with dementia avoid harmful meds (13650) ................................ 23
HEDIS elderly chronic renal failure avoid harmful med (13649) .......................... 23
New start atypical antipsychotic diabetes screening (16869) .............................. 24
Warfarin 2 month prothrombin time test (NQF) (219) .................................... 25

Endocrine Measures: Diabetes ........................................................................... 25
DM and insulin use evidence of self monitoring (NQF) (10228) ......................... 25
DM on meds had creatinine test (NQF) (11399) .............................................. 26
HEDIS diabetes annual hemoglobin A1c (381) .............................................. 26
HEDIS diabetes annual LDL (380) ............................................................... 27
Diabetes hypertension nephropathy on ACE or ARB (172) .............................. 28
HEDIS diabetes annual nephropathy screening (382) ...................................... 28
New diabetes on metformin (2431) ............................................................... 29

Endocrine Measures: Dyslipidemia ................................................................. 29
Lipid Rx noncompliance (NQF) (11373) .......................................................... 29
Dyslipidemia new med 3 month lipid panel (NQF) (185) ................................. 30

Gastroenterology ............................................................................................ 31
IBD and chronic steroid bone density test (413) .............................................. 31
Hepatitis C viral load testing (NQF) (426) ...................................................... 31
Hepatitis C high risk needs screening (17915) .............................................. 32
No colorectal cancer screening > 85 (17914) .................................................. 33

Gynecology ..................................................................................................... 33
Endometrial ablation appropriate prior workup (NQF) (10217) ....................... 33

Hematology Measures .................................................................................... 34
Pulmonary embolism antithrombotic med (NQF) (424) .................................... 34
Deep vein thrombosis antithrombotic med (NQF) (425) ................................. 34

Behavioral Health .......................................................................................... 35
Depression avoid anxiolytic without antidepressant (222) ............................... 35
HEDIS antidepressant med at least 12 weeks (397) ....................................... 36
HEDIS antidepressant med at least 6 months (388) ....................................... 36
New bipolar disorder on antimanic agent (NQF) (2432) ............................... 37
HEDIS ADHD med follow-up visit within 30 days (3804) ............................ 38
HEDIS ADHD med follow-up visits within 9 months (3812) ....................... 38

Nephrology ..................................................................................................... 39
Chronic kidney disease need annual lipid test (NQF) (11382) ......................... 39
Chronic kidney disease monitor calcium (NQF) (11378) .............................. 39
Chronic kidney disease monitor parathyroid hormone (11374) ........................................ 40
Chronic kidney disease monitor phosphorus (NQF) (11379) ........................................ 41

Neurology ......................................................................................................................... 41
Migraine had prophylactic medication (NQF) (11401) ....................................................... 41
New dementia thyroid and B12 tests (2686) ................................................................... 42

Ophthalmology .................................................................................................................. 43
Cataract surgery and no post-op complication (4393) ...................................................... 43

Otolaryngology .................................................................................................................. 43
Otitis media effusion no systemic antimicrobials (4396) ................................................... 43
Acute otitis externa avoid systemic antibiotics (4397) .................................................... 44
Tymanostomy tube hearing test (NQF) (4399) ................................................................. 44
Postoperative complications within one week of tonsillectomy (17912) ...................... 45
Postoperative complications within one week of septoplasty (17913) ......................... 45

Prenatal Care Measures ..................................................................................................... 46
Pregnant woman needs Hepatitis B screening (NQF) (11387) ......................................... 46
Pregnant woman needs HIV screening (NQF) (11381) .................................................... 46
Pregnant woman needs syphilis screening (NQF) (11386) ............................................... 47

Preventive Health Measures: Women’s Health ................................................................. 48
High risk cervical cancer screening (NQF) (168) ............................................................. 48
Cervical cancer screen 21-29 years of age (20542) ........................................................... 48
Cervical cancer screen 30-64 years of age (183) .............................................................. 49
HEDIS chlamydia annual screening (384) ...................................................................... 49
HEDIS breast cancer screening in past 2 years (182) ....................................................... 50

Preventive Health Measures: Well Child Visits ................................................................. 51
Age 0-1 year old appropriate office visits (5607) .............................................................. 51
Age 1-3 years old appropriate office visits (5608) ............................................................ 51
Age 3-11 years old appropriate office visits (7842) .......................................................... 52
Age 12-18 years old appropriate office visits (7843) ......................................................... 52

Pulmonary Measures: Asthma .......................................................................................... 53
Persistent asthma beta-2 agonist (228) ............................................................................ 53
HEDIS persistent asthma appropriate med (2376) ......................................................... 53
Asthma inappropriate ED use (17895) ............................................................................. 54
Asthma spirometry to confirm diagnosis (17945) ............................................................ 54
Asthma needs periodic spirometry (17910) ..................................................................... 55

Pulmonary Measures: COPD ......................................................................................... 55
COPD on long acting bronchodilator (NQF) (11397) ....................................................... 55
COPD spirometry to confirm diagnosis (NQF) (10216) .......................................................... 56
Asthma or COPD avoid beta-2 agonist overuse (225) ............................................................ 57
HEDIS COPD corticosteroid post discharge (6747) .................................................................. 57
HEDIS COPD bronchodilator post discharge (7304) ................................................................. 58
COPD inappropriate ED use (17911) ....................................................................................... 59

Pulmonary Measures: Other Respiratory .................................................................................. 59

HEDIS pharyngitis appropriate testing (385) .......................................................... 59
HEDIS upper respiratory infection appropriate med (386) ........................................ 60
HEDIS acute bronchitis avoid antibiotics (3817) ................................................................. 60

Rheumatology: Osteoporosis .................................................................................................. 61

Osteoporosis on pharmacological therapy (NQF) (11380) .................................................. 61
Osteopenia and chronic steroids on osteoporosis Rx (NQF) (10226) .............................. 61
Steroid use osteoporosis screening (NQF) (11390) ............................................................... 62
HEDIS osteoporosis management post fracture (389) .......................................................... 63

Rheumatology: Rheumatoid arthritis ...................................................................................... 63

HEDIS rheumatoid arthritis DMARD therapy (3794) .......................................................... 63
Rheumatoid Arthritis DMARD baseline CBC (NQF) (4311) .................................................. 64
Rheumatoid arthritis DMARD baseline creatinine (NQF) (4361) ...................................... 64
Rheumatoid arthritis DMARD baseline AST or ALT (NQF) (4362) ..................................... 65
Rheumatoid arthritis hydroxychloroquine eye exam (NQF) (2426) ................................. 66
Methotrexate 3 month CBC test (NQF) (2690) ................................................................. 67
Methotrexate 3 month creatinine test (NQF) (2688) .......................................................... 67
Methotrexate 3 month liver function test (NQF) (2687) ......................................................... 68
Cancer Surveillance

Breast cancer history annual surveillance (NQF) (11923)

Measure Description:

This measure identifies female patients with history of breast cancer who had breast cancer surveillance in the past 12 months.

Numerator: Patients in the denominator who had breast cancer surveillance during the measurement year.

Denominator: Female patients over 18 years old with a history of breast cancer, excluding patients with a history of mastectomies and bilateral breast implants.

Specialties:

*Family Practice,* General Practice,* General Surgery,* Internal Medicine,* Obstetrics & Gynecology

Citations:


Prostate cancer annual cancer surveillance (NQF) (10220)

Measure Description:

This measure identifies male patients with history of prostate cancer who have had their PSA monitored during the measurement year.

Numerator: Patients in the denominator who have had a PSA test or evidence of PSA monitoring during the measurement year

Denominator: Male patients diagnosed with prostate cancer anytime in the past prior to the measurement year, excluding patients actively being treated for prostate cancer during the measurement year.
Specialties:

*Family Practice,*General Practice,*Internal Medicine,*Urology

Citations:


Cardiac Measures: Atrial Fibrillation

Atrial fibrillation and stroke risk on warfarin (NQF) (11941)

Measure Description:

This measure identifies patients with atrial fibrillation and other stroke risk who are taking oral anticoagulants.

**Numerator:** Patients in the denominator who have evidence of oral anticoagulants use with days supply extending within 30 days of the analysis date or evidence of long-term anticoagulation in the past.

**Denominator:** Adult patients at least 25 years old with atrial fibrillation and major stroke risk factors including prior stroke, mitral stenosis, or mitral valve replacement, or 2 of the following: age>75, diabetes, hypertension, or CHF.

Specialties:

*Cardiology,*Family Practice,*General Practice,*Internal Medicine

Citations:


New Atrial Fibrillation: Thyroid Function Test (1972)

**Measure Description:**

This measure identifies patients with new-onset atrial fibrillation during the measurement year who have had a thyroid function test 6 weeks before or after the diagnosis of atrial fibrillation.

**Numerator:** Patients in the denominator who had a thyroid function test 6 weeks before or after the diagnosis of atrial fibrillation.

**Denominator:** Adult patients with a new diagnosis of atrial fibrillation during the first 10.5 months of the measurement year.

**Specialties:**

*Cardiology,*Family Practice,*General Practice,*Internal Medicine

**Citations:**


Atrial fibrillation warfarin INR check (211)

**Measure Description:**

This measure identifies patients with atrial fibrillation diagnosed during the measurement year who started warfarin and who had an INR test within 2 weeks after the warfarin start date.

**Numerator:** Patients in the denominator who had an INR test within 2 weeks after the warfarin start date.

**Denominator:** Patients diagnosed with atrial fibrillation newly started on warfarin, excluding those with any ER visit or hospitalization 14 days after the warfarin start date.

**Specialties:**

*Cardiology,*Family Practice,*General Practice,*Internal Medicine
Citations:


Cardiac Measures: Heart Failure

Heart failure ACE-I or ARB use (NQF) (11931)

Measure Description:

This measure identifies patients with heart failure who are on an ACE-I or ARB medication.

**Numerator:** Patients in the denominator who are on an ACE-I or ARB medication in the last month of the measurement year.

**Denominator:** Patients 18 years or older who have a history of heart failure.

Specialties:

*Cardiology,*Family Practice,*General Practice,*Internal Medicine

Citations:


Heart failure on beta blocker (NQF) (11933)

Measure Description:

This measure identifies patients with heart failure who are on a beta blocker.

Specialties:

*Cardiology,*Family Practice,*General Practice,*Internal Medicine

Citations:

CHF avoid DHP calcium channel blocker (175)

Measure Description:

This measure identifies patients with HF who are not taking a non-dihydropyridine calcium channel blocker (non-DHP CCB).

Numerator: Patients in the denominator who are not taking a non-dihydropyridine calcium channel blocker (non-DHP CCB) during the last 6 months of the measurement year.

Denominator: Patients with HF diagnosed prior to the measurement year.

Specialties:

*Cardiology,*Family Practice,*General Practice,*Internal Medicine

Citations:


Cardiac Measures: Coronary Heart Disease

CHD post-MI on ACE inhibitor (NQF) (398)

Measure Description:

This measure identifies patients with ST elevation MI (STEMI), or non-ST elevation MI (NSTEMI) plus a history of hypertension, HF, and/or diabetes prior to the measurement year who are taking an ACEI or an ARB during the measurement year.

Numerator: Patients in the denominator with at least 1 prescription claim for an ACEI or an ARB during the measurement year.
**Denominator:** Patients with STEMI, or NSTEMI with hypertension, HF, and/or diabetes, prior to the measurement year who do not have a contraindication to ACEI/ARB therapy (contraindications include hyperkalemia, active pregnancy, and renal artery stenosis).

**Specialties:**

*Cardiology,* Family Practice, *General Practice,* Internal Medicine

**Citations:**


**CHD post-MI on beta blocker (157)**

**Measure Description:**

This measure identifies patients diagnosed with acute myocardial infarction (AMI) prior to the measurement year who are taking a beta blocker during the measurement year.

**Numerator:** Patients in the denominator who have =>1 Rx claim for a beta blocker during the measurement year.

**Denominator:** Patients with a diagnosis of AMI prior to the measurement year who do not have a contraindication to beta blockers (contraindications include: history of asthma, presence of inhaled corticosteroids, hypotension, 2nd- or 3rd-degree heart block or sinus bradycardia with no history of pacemaker, or COPD).

**Specialties:**

*Cardiology,* Family Practice, *General Practice,* Internal Medicine

**Citations:**


HEDIS CHD cholesterol management (3798)

Measure Description:

This measure identifies patients 18–75 years old discharged alive for acute myocardial infarction (AMI), coronary bypass graft (CABG), or percutaneous transluminal coronary angioplasty (PTCA) during the year prior to the measurement year, or who had a diagnosis of ischemic vascular disease (IVD) during or in the year prior to the measurement year, who had a LDL-C check during the measurement year.

Numerator: Patients in the denominator who had a lipid test within the measurement year.

Denominator: Patients with CHD diagnosed prior to the measurement year.

Specialties:

*Cardiology,*Family Practice,*General Practice,*Internal Medicine

Citations:


Bare metal stent antiplatelet within 30 days (2682)

Measure Description:

This measure identifies patients undergoing percutaneous coronary intervention (PCI) with placement of a bare metal intracoronary stent during the first 11 months of the
measurement year, who had a prescription for an antiplatelet Rx within 30 days after stent placement.

**Numerator:** Patients in the denominator with a prescription for an antiplatelet Rx within 30 days following stent placement.

**Denominator:** Patients who underwent PCI with placement of a bare metal intracoronary stent, during the first 11 months of the measurement year, excluding those with contraindications to antiplatelets. Contraindications are approximated by a history, within the past three years, of peptic ulcer disease, intracranial hemorrhage, gastrointestinal bleeding, and hemorrhagic tendencies.

**Specialties:**

*Cardiology,* Family Practice,* General Practice,* Internal Medicine

**Citations:**


**Drug-eluting stent antiplatelet 3 months (NQF) (4141)**

**Measure Description:**
This measure identifies patients undergoing percutaneous coronary intervention (PCI) with placement of a drug-eluting intracoronary stent during the first 9 months of the measurement year, who had consistent use of an antiplatelet Rx for 3 months following stent placement.

**Numerator:** Patients in the denominator who are taking an antiplatelet Rx consistently in the 3 months following placement of the drug-eluting intracoronary stent.

**Denominator:** Patients who underwent PCI with placement of a drug-eluting intracoronary stent, during the first 9 months of the measurement year, excluding those with contraindications to antiplatelets. Contraindications are approximated by a history, within the past three years, of peptic ulcer disease, intracranial hemorrhage, gastrointestinal bleeding, and hemorrhagic tendencies.

**Specialties:**

*Cardiology,* *Family Practice,* *General Practice,* *Internal Medicine*

**Citations:**


**HEDIS MI hospitalization beta blocker 6 months (383)**

**Measure Description:**

The percentage of members 18 years of age and older during the measurement year who were hospitalized and discharged alive from 6 months prior to the measurement year to 6 months before the end of the measurement year with a diagnosis of AMI and who received persistent beta-blocker treatment for 6 months after discharge.

**Numerator:** Patients in the denominator who have ≥135 days supply of a beta blocker medication in the 6 months post AMI discharge.

**Denominator:** Patients hospitalized and discharged with an AMI between July 1 of the year prior to the measurement year and June 30 of the measurement year, who do not have a contraindication to beta blockers (contraindications include: history of asthma or
use of asthma medications, hypotension, 2nd- or 3rd-degree heart block or sinus bradycardia with no history of pacemaker, or COPD).

Specialties:

*Cardiology,*Family Practice,*General Practice,*Internal Medicine

Citations:


Cardiac Measures: Hypertension

HTN had creatinine test (11398)

Measure Description:

This measure identifies patients with hypertension and receiving an ACE inhibitor or ARB, who had a serum creatinine test during the measurement year.

Numerator: Patients in the denominator who had a serum creatinine test during the measurement year (and 90 days after).

Denominator: Patients 18 years or older who have been diagnosed with hypertension between 1.5 to 3 years ago and who have received an ACE inhibitor or ARB consistently during the past 15 months prior to the end of the, measurement year, and who do not have a diagnosis of end stage renal disease during the measurement year (this exclusion is only applied if the numerator is not met).

Specialties:

*Cardiology,*Family Practice,*General Practice,*Internal Medicine

Citations:


New hypertension glucose test (152)

Measure Description:

This measure identifies patients with newly diagnosed hypertension during the measurement year with a lab claim for a serum glucose test at the time of diagnosis, if not done in the 6 months prior to diagnosis.

Numerator: Patients in the denominator who had a serum or plasma glucose test within 30 days after initial diagnosis of hypertension.

Denominator: Patients who meet criteria for newly diagnosed hypertension during the measurement year and who did not have a serum or plasma glucose test between 180 days and 31 days prior to diagnosis.

Specialties:

*Cardiology,*Family Practice,*General Practice,*Internal Medicine

Citations:


New hypertension potassium test (153)

Measure Description:

This measure identifies patients with newly diagnosed hypertension during the measurement year with a lab claim for a serum potassium test at the time of diagnosis, if not done in the 6 months prior to diagnosis.

Specialties:

*Cardiology,*Family Practice,*General Practice,*Internal Medicine

Citations:

New hypertension lipid test (154)

Measure Description:

This measure identifies patients with newly diagnosed hypertension during the measurement year with a lab claim for a serum lipid panel test at the time of diagnosis, if not done in the year prior to diagnosis.

Numerator: Patients in the denominator who had a lipid panel test within 30 days after initial diagnosis of hypertension.

Denominator: Patients who meet criteria for newly diagnosed hypertension during the measurement year and who did not have a serum lipid panel test between 365 days and 31 days prior to diagnosis.

Specialties:

*Cardiology,*Family Practice,*General Practice,*Internal Medicine

Citations:


Hypertension avoid SA DHP calcium channel blocker (174)

Measure Description:

This measure identifies the percentage of patients with hypertension diagnosed before the measurement year who had fewer than 2 prescription claims for short-acting dihydropyridine calcium channel blockers (SA DHP CCB) within the past 6 months.

Numerator: Patients in the denominator who had fewer than two prescription claims for SA-DHP-CCBs during the past 6 months.

Denominator: Patients with hypertension diagnosed before the measurement year.

Specialties:

*Cardiology,*Family Practice,*General Practice,*Internal Medicine

Citations:


**Drug Safety Measures**

**Amiodarone baseline thyroid test (NQF) (412)**

**Measure Description:**

This measure identifies patients who had a TSH baseline measurement at the start of amiodarone therapy.

**Numerator:** Patients in the denominator who had TSH baseline measurement within 60 days prior to or 30 days after the start of amiodarone.

**Denominator:** Adult patients who started amiodarone during the first 11 months of the measurement year, without evidence of total thyroidectomy in the past.

**Specialties:**

*Cardiology,*Family Practice,*General Practice,*Internal Medicine

**Citations:**


Batcher EL, Tang C. Thyroid Function abnormalities during amiodarone therapy for persistent atrial fibrillation. AJM. 2007. 120:880-885.


**Amiodarone annual thyroid test (20442)**

**Measure Description:**

This measure identifies patients on chronic amiodarone therapy who had annual TSH measurement.
**Numerator:** Patients in the denominator who had annual TSH measurement during the measurement year.

**Denominator:** Adult patients on chronic amiodarone therapy for at least 18 months before the end of the measurement period, without evidence of total thyroidectomy in the past.

**Specialties:**

*Cardiology,* *Family Practice,* *General Practice,* *Internal Medicine*

**Citations:**


Batcher EL, Tang C. Thyroid Function abnormalities during amiodarone therapy for persistent atrial fibrillation. AJM. 2007. 120:880-885.


**HEDIS ACEI or ARB annual potassium and creatinine (395)**

**Measure Description:**

This measure identifies patients age 18 or older who received at least 180 days supply for ACE inhibitors or ARBs during the measurement year who had at least 1 serum potassium and either a serum creatinine or a blood urea nitrogen (BUN) test during the measurement year.

**Numerator:** Patients in the denominator who had at least 1 serum potassium and either a serum creatinine or a BUN test during the measurement year.

**Denominator:** Patients who had at least 180 days supply for ACE inhibitors or ARBs during the measurement year.

**Specialties:**

*Cardiology,* *Family Practice,* *General Practice,* *Internal Medicine*

**Citations:**

**HEDIS digoxin annual potassium and creatinine (377)**

**Measure Description:**

This measure identifies patients age 18 or older who had at least 180 days supply for digoxin during the measurement year who had at least 1 serum potassium and either a serum creatinine or a blood urea nitrogen (BUN) therapeutic monitoring test during the measurement year.

**Numerator:** Patients in the denominator who had at least 1 serum potassium and either a serum creatinine or a BUN test during the measurement year.

**Denominator:** Patients who had at least 180 days supply for digoxin during the measurement year.

**Specialties:**

*Cardiology,* Family Practice, *General Practice,* Internal Medicine

**Citations:**


**HEDIS diuretics annual potassium and creatinine (394)**

**Measure Description:**

This measure identifies patients age 18 or older who had at least 180 days supply for diuretics during the measurement year who had at least 1 serum potassium and either a serum creatinine or a blood urea nitrogen (BUN) therapeutic monitoring test during the measurement year.

**Numerator:** Patients in the denominator who had at least 1 serum potassium and either a serum creatinine or a BUN therapeutic monitoring test during the measurement year.

**Denominator:** Patients who had at least 180 days supply for diuretics during the measurement year.
Specialties:

*Cardiology,*Family Practice,*General Practice,*Internal Medicine

Citations:


HEDIS anticonvulsants annual drug level (390)

Measure Description:

This measure identifies patients age 18 or older who had at least 180 days supply for anticonvulsants during the measurement year who had at least 1 serum drug measurement (for the prescribed drug) during the measurement year.

**Numerator:** Patients in the denominator who had at least 1 serum drug measurement (for the prescribed drug) during the measurement year.

**Denominator:** Patients who had at least 180 days supply for anticonvulsants during the measurement year. Targeted drugs include carbamazepine, phenobarbital, phenytoin, and valproic acid.

Specialties:

*Family Practice,*General Practice,*Internal Medicine,*Neurology

Citations:


Clozapine white blood cell count (401)

Measure Description:

This measure identifies the percentage of patients taking clozapine during the measurement year who have had a WBC test.

Specialties:
*Family Practice,*General Practice,*Internal Medicine,*Psychiatry

Citations:


Lithium annual creatinine test (NQF) (2427)

Measure Description:

This measure identifies the percentage of patients taking lithium who have had at least one creatinine test after the earliest observed lithium prescription during the measurement year.

Specialties:

*Family Practice,*General Practice,*Internal Medicine,*Psychiatry

Citations:


Lithium annual thyroid function test (NQF) (2428)

Measure Description:

This measure identifies the percentage of patients taking lithium who have had at least one thyroid function test after the earliest observed lithium prescription during the measurement year.

**Numerator**: Patients in the denominator who received a thyroid function test after the earliest observed lithium prescription during the measurement year.

**Denominator**: Patients who received at least a 292-day supply of lithium during the measurement year.

Specialties:
*Family Practice,*General Practice,*Internal Medicine,*Psychiatry

**Citations:**


**Lithium annual drug level test (NQF) (2424)**

**Measure Description:**

This measure identifies the percentage of patients taking lithium who have had at least one lithium level test after the earliest observed lithium prescription during the measurement year.

**Numerator:** Patients in the denominator who received a lithium level test after the earliest observed lithium prescription during the measurement year.

**Denominator:** Patients who received at least a 292-day supply of lithium during the measurement year.

**Specialties:**

*Family Practice,*General Practice,*Internal Medicine,*Psychiatry

**Citations:**


**Benign prostatic hypertrophy avoid anticholinergic (423)**

**Measure Description:**

This measure identifies the percentage of male patients with benign prostatic hyperplasia (BPH) without claims for anticholinergic medication in the last 6 months of the measurement year.

**Numerator:** Patients in the denominator without prescriptions for anticholinergic medications in the last 6 months of the measurement year.
**Denominator:** Men with history of BPH, but without history of TURP procedure or radical prostatectomy.

**Specialties:**

*Family Practice,* *General Practice,* *Internal Medicine,* *Urology*

**Citations:**


**HEDIS elderly with dementia avoid harmful meds (13650)**

**Measure Description:**

This measure identifies patients with a history of dementia or dementia medications who have not been prescribed antiemetics, antipsychotics, benzodiazepines, tricyclic antidepressants, H2 Receptor Antagonists, nonbenzodiazepine hypnotics or anticholinergic agents.

**Numerator:** Patients without a prescription for antiemetics, antipsychotics, benzodiazepines, tricyclic antidepressants, H2 Receptor Antagonists, nonbenzodiazepine hypnotics or anticholinergic agents from the earliest identified date of dementia diagnosis or medication to December 31 of the current year.

**Denominator:** Patients over 65 years old with a diagnosis of dementia or a dementia medication from January 1 of the previous year to December 1 of the current year.

**Specialties:**

*Family Practice,* *General Practice,* *Internal Medicine*

**Citations:**


**HEDIS elderly chronic renal failure avoid harmful med (13649)**

**Measure Description:**
This measure identifies patients with a history of chronic renal failure who have not been prescribed an NSAID or Cox-2 Selective NSAID.

**Numerator:** Patients without a prescription for a nonaspirin NSAID or a Cox-2 Selective NSAID from the earliest identified date of CRF to Dec. 1 of the current year.

**Denominator:** Patients over 65 years old with a diagnosis of chronic renal failure from Jan. 1 of the previous year to Dec. 1 of the current year.

**Specialties:**
- Family Practice
- General Practice
- Internal Medicine
- Nephrology

**Citations:**


---

**New start atypical antipsychotic diabetes screening (16869)**

**Measure Description:**

This measure identifies patients of any age, including pediatric patients, with a new start of an atypical antipsychotic medication who have had a diabetes screening test since starting the medication.

**Numerator:** Patients with a screening test for hyperglycemia in the 16 weeks following the start of the atypical antipsychotic agent; acceptable hyperglycemia tests: fasting plasma glucose, HbA1c, or random plasma glucose.

**Denominator:** Patients newly started on an atypical antipsychotic agent with no atypical antipsychotic use in the previous 6 months. Targeted drugs include Iloperidone, Paliperidone, Risperidone, Clozapine, Quetiapine, Asenapine, Olanzapine, Aripiprazole, Lurasidone, and Ziprasidone.

**Specialties:**
- Family Practice
- General Practice
- Internal Medicine
- Psychiatry

**Citations:**


**Warfarin 2 month prothrombin time test (NQF) (219)**

**Measure Description:**

This measure identifies patients taking warfarin during the measurement year who had at least 1 PT/INR test within 60 days after the earliest detected warfarin prescription.

**Numerator:** Patients in the denominator who had a PT/INR test within 60 days after the earliest observed warfarin prescription during the measurement year.

**Denominator:** Patients who are taking warfarin during the measurement year, excluding those with any ER visit or hospitalization during the 60 days after the earliest observed warfarin prescription during the measurement year.

**Specialties:**

*Family Practice,* General Practice, *Internal Medicine*

**Citations:**


**Endocrine Measures: Diabetes**

**DM and insulin use evidence of self monitoring (NQF) (10228)**

**Measure Description:**

This measure identifies patients with diabetes taking insulin who have evidence of proper self-monitoring blood glucose testing during the measurement year.

**Numerator:** Patients in the denominator who filled a prescription for a glucometer, blood glucose test strips, or other supplies used for blood glucose self-monitoring, during the measurement year and the 3 months prior to the start of the measurement year.
Denominator: Patients between 18 and 75 years old with a diagnosis of diabetes or who took an oral hypoglycemic prescription during the measurement year or the year prior to the measurement year, who have also filled a prescription for insulin in the last 7 months of the measurement year.

Specialties:

*Endocrinology,*Family Practice,*General Practice,*Internal Medicine

Citations:


DM on meds had creatinine test (NQF) (11399)

Measure Description:

This measure identifies adults with diabetes who have had a serum creatinine test during the measurement year.

Numerator: Patients in the denominator who have had a serum creatinine test during the 15 months prior to the end of the measurement period.

Denominator: Patients between 18 and 75 years old with a diagnosis of diabetes or patients who have an oral hypoglycemic or insulin prescription during the measurement year or the year prior. Exclude members with =>1 encounters during the measurement year for polycystic ovaries, gestational diabetes, or steroid-induced diabetes.

Specialties:

*Endocrinology,*Family Practice,*General Practice,*Internal Medicine

Citations:


HEDIS diabetes annual hemoglobin A1c (381)

Measure Description:

This measure identifies patients between 18 and 75 years old who have diabetes and who had at least 1 HbA1c test during the measurement year.
Numerator: Patients in the denominator who had at least 1 serum HbA1c test during the measurement year.

Denominator: Patients with diabetes diagnosed during the measurement year or the year prior to the measurement year, excluding members with a history of polycystic ovaries, or encounters for gestational diabetes or steroid-induced diabetes during the 2 years prior to the end of the measurement period.

Specialties:
- Endocrinology, Family Practice, General Practice, Internal Medicine

Citations:

HEDIS diabetes annual LDL (380)

Measure Description:
This measure identifies patients between 18 and 75 years old who have diabetes and who had an LDL-C level checked during the measurement year.

Numerator: Patients in the denominator who had an LDL-C level checked during the measurement year.

Denominator: Patients with diabetes diagnosed during the measurement year or the year prior to the measurement year, excluding members with a history of polycystic ovaries, or encounters for gestational diabetes or steroid-induced diabetes during the 2 years prior to the end of the measurement period.

Specialties:
- Cardiology, Endocrinology, Family Practice, General Practice, Internal Medicine

Citations:
Diabetes hypertension nephropathy on ACE or ARB (172)

Measure Description:

This measure identifies patients with diabetes plus hypertension or nephropathy who are taking an ACE inhibitor or ARB during the measurement year.

Numerator: Patients in the denominator who have =>1 Rx claim for an ACE inhibitor or ARB or direct renin inhibitor during the measurement year.

Denominator: Patients with past medical history of diabetes plus hypertension or nephropathy diagnosed prior to the measurement year, excluding members with a history of polycystic ovaries, or encounters for gestational diabetes or steroid-induces diabetes during the 2 years prior to the end of the measurement period.

Specialties:

*Cardiology,*Endocrinology,*Family Practice,*General Practice,*Internal Medicine

Citations:


HEDIS diabetes annual nephropathy screening (382)

Measure Description:

This measure identifies patients between 18 and 75 years old who have diabetes and at least one nephropathy screening; or who had evidence of medical attention for existing nephropathy (diagnosis or treatment of nephropathy), who are taking ACE-I/ARBs, or who have had at least one visit with a nephrologist.

Numerator: The number of patients from the denominator who during the measurement year had at least one test for nephropathy screening; or who had evidence of medical attention for existing nephropathy (diagnosis or treatment of nephropathy), who are taking ACE-I/ARBs, or who have had at least one visit with a nephrologist.
**Denominator**: Patients with diabetes diagnosed during the measurement year or the year prior to the measurement year, excluding members with a history of polycystic ovaries, or encounters for gestational diabetes or steroid-induced diabetes during the 2 years prior to the end of the measurement period.

**Specialties**:  
*Endocrinology,* Family Practice,* General Practice,* Internal Medicine

**Citations**:  

**New diabetes on metformin (2431)**

**Measure Description**:  
This measure identifies the percentage of patients newly diagnosed with diabetes type 2 who were treated with Metformin within 3 months following diagnosis, excluding patients who were immediately started on insulin therapy.

**Numerator**: Patients in the denominator who have received at least 1 prescription claim for Metformin from diabetes diagnosis to 90 days after diagnosis.

**Denominator**: Patients newly diagnosed with diabetes type 2 during the first 9 months of the measurement year, excluding those with insulin prescription claims.

**Specialties**:  
*Endocrinology,* Family Practice,* General Practice,* Internal Medicine

**Citations**:  

**Endocrine Measures: Dyslipidemia**

**Lipid Rx noncompliance (NQF) (11373)**

**Measure Description**:  

This measure identifies patients on a lipid medication who have remained adherent to taking the medication regularly.

**Numerator:** Patients in the denominator who have taken their lipid-lowering medication at least 80% of the time during the 6-month period after the initial prescription fill date.

**Denominator:** Patients at least 19 years old with a diagnosis of hyperlipidemia who filled a prescription for a lipid-lowering medication sometime between 6 and 18 months before the end of the measurement year, and who had at least 60 days of medication supply in the 6 months following the earliest prescription fill in this time period.

**Specialties:**

*Cardiology,*Endocrinology,*Family Practice,*General Practice,*Internal Medicine

**Citations:**


**Dyslipidemia new med 3 month lipid panel (NQF) (185)**

**Measure Description:**

This measure identifies patients who started lipid-lowering medication during the measurement year and had a lipid panel checked within 3 months after starting drug therapy.

**Numerator:** Patients in the denominator who had a serum lipid panel drawn within 3 months following start of lipid-lowering therapy.

**Denominator:** Patients newly started on lipid-lowering therapy during the first 9 months of the measurement year.

**Specialties:**
Citations:


Gastroenterology

IBD and chronic steroid bone density test (413)

Measure Description:

This measure identifies patients with inflammatory bowel disease (Crohn's disease, ulcerative colitis) who have taken chronic steroids during the measurement year and have undergone a bone mineral density test within the past 2 years.

Numerator: Patients in the denominator who have undergone a bone mineral density test within the past 2 years.

Denominator: Patients with inflammatory bowel disease (Crohn's disease, ulcerative colitis) diagnosed before the measurement year, who have taken chronic steroids over 80% MPR during the first half of the measurement year.

Specialties:

*Family Practice,*Gastroenterology,*General Practice,*Internal Medicine

Citations:


Hepatitis C viral load testing (NQF) (426)

Measure Description:
This measure identifies patients with Hepatitis C (HCV) who began HCV antiviral therapy during the measurement year and had HCV Viral Load testing prior to initiation of antiviral therapy.

**Numerator:** Patients in the denominator who had an HCV Viral Load test prior to initiation of antiviral therapy.

**Denominator:** HCV patients who started HCV antiviral therapy during the measurement year.

**Specialties:**

*Family Practice,*Gastroenterology,*General Practice,*Internal Medicine

**Citations:**


**Hepatitis C high risk needs screening (17915)**

**Measure Description:**

This measure identifies patients at high risk for Hepatitis C (i.e., members who have HIV) who received an appropriate Hepatitis C screening test. The measure only considers a recent initial diagnosis of HIV to identify individuals at high risk of current infection with Hepatitis C virus (HCV). Consideration of other recognized risk factors is not feasible because information is not available concerning when the initial exposure occurred, and whether HCV testing had already been performed, preceding the time span covered by the administrative data set.

**Numerator:** Patients in the denominator who were screened for Hepatitis C during the measurement year.

**Denominator:** Patients => 18 years of age with HIV diagnosed prior to the measurement year.

**Specialties:**
*Family Practice,*Gastroenterology,*General Practice,*Internal Medicine

Citations:


**No colorectal cancer screening > 85 (17914)**

**Measure Description:**

This measure identifies patients 86 years or older who did not receive an inappropriate colorectal cancer screening.

**Specialties:**

*Gastroenterology

Citations:


**Gynecology**

**Endometrial ablation appropriate prior workup (NQF) (10217)**

**Measure Description:**

This measure identifies female patients who have had appropriate endometrial sampling performed prior to undergoing an endometrial ablation procedure.

**Numerator:** Patients in the denominator who received endometrial sampling or hysteroscopy with biopsy during the 12-month period prior to the date of endometrial ablation.

**Denominator:** Female patients who had an endometrial ablation procedure during the measurement year.

**Specialties:**

*Obstetrics & Gynecology,Gynecology

Citations:


**Hematology Measures**

**Pulmonary embolism antithrombotic med (NQF) (424)**

**Measure Description:**

This measure identifies patients with pulmonary embolism (PE) on anticoagulation for at least 3 months after the diagnosis.

**Numerator:** Patients in the denominator who had at least 3 months of oral anticoagulation after the event or patients showing compliance with anticoagulation therapy as indicated by a Home PT Monitoring device or multiple instances of prothrombin time testing over the 3-month period.

**Denominator:** Patients diagnosed with a PE more than 3 months prior to the end of the measurement year, who do not have contraindications to oral anticoagulation therapy (contraindications include: evidence of eye surgery, GI bleed, aortic dissection, cerebral aneurysm, pericarditis, bacterial endocarditis, pregnancy, bleeding diatheses, or head trauma during or 1 year prior to the measurement year) and who do not have an IVC filter in the 90 days after the onset of PE.

**Specialties:**

*Family Practice,*General Practice,*Hematology & Oncology,*Internal Medicine,*Pulmonary Disease

**Citations:**


**Deep vein thrombosis antithrombotic med (NQF) (425)**

**Measure Description:**

This measure identifies patients with lower extremity deep vein thrombosis (DVT) on anticoagulation for at least 3 months after diagnosis.

**Numerator:** Patients in the denominator who had at least 3 months of oral anticoagulation after the event or patients showing compliance with anticoagulation therapy as indicated by a Home PT Monitoring device or multiple instances of prothrombin time testing over the 3-month period.

**Denominator:** Patients diagnosed with a DVT more than 3 months prior to the end of the measurement year, who do not have contraindications to oral anticoagulation therapy (contraindications include: evidence of eye surgery, GI bleed, aortic dissection, cerebral aneurysm, pericarditis, bacterial endocarditis, pregnancy, bleeding diatheses, or head trauma during or 1 year prior to the measurement year) and who do not have an IVC filter in the 90 days after the onset of DVT.

**Specialties:**

*Family Practice,*General Practice,*Hematology & Oncology,*Internal Medicine,*Pulmonary Disease

**Citations:**

therapy as indicated by a Home PT Monitoring device or multiple instances of prothrombin time testing over the 3-month period.

**Denominator:** Patients diagnosed with a lower extremity DVT more than 3 months prior to the end of the measurement year, who do not have contraindications to oral anticoagulation therapy (contraindications include: evidence of eye surgery, GI bleed, aortic dissection, cerebral aneurysm, pericarditis, bacterial endocarditis, pregnancy, bleeding diatheses, or head trauma during or 1 year prior to the measurement year) and who do not have an IVC filter in the 90 days after the onset of PE. This measure identifies patients with lower extremity deep vein thrombosis (DVT) on anticoagulation for at least 3 months after diagnosis.

**Specialties:**

*Family Practice,* General Practice,* Hematology & Oncology,* Internal Medicine

**Citations:**


**Behavioral Health**

**Depression avoid anxiolytic without antidepressant (222)**

**Measure Description:**

This measure identifies patients newly diagnosed with depression during the first 9 months of the measurement year who have not received an anti-anxiety agent as the sole treatment for their depression.

**Numerator:** Patients in the denominator who have not received an anti-anxiety agent as sole treatment for their depression between 30 days before the onset of depression and 90 days after that.

**Denominator:** Patients with newly diagnosed depression during the first 9 months of the measurement year.

**Specialties:**

*Family Practice,* General Practice,* Internal Medicine,* Psychiatry

**Citations:**

**HEDIS antidepressant med at least 12 weeks (397)**

**Measure Description:**

The percentage of members 18 years of age and older with a diagnosis of major depression who were treated with antidepressant medication, and who remained on medication for at least 12 weeks of a 114-day period following the earliest dispensing event.

**Numerator:** Patients in the denominator who were maintained on antidepressant therapy for at least 84 days in the 114-day period following start of antidepressant.

**Denominator:** Patients with at least one dispensing event for an antidepressant medication during the 12-month window starting on May 1 of the year prior to the measurement year and ending on April 30 of the measurement year, with a diagnosis of major depression within 60 days from the earliest dispensing event.

**Specialties:**

*Family Practice,*General Practice,*Internal Medicine,*Psychiatry

**Citations:**


---

**HEDIS antidepressant med at least 6 months (388)**

**Measure Description:**

The percentage of members 18 years of age and older with a diagnosis of major depression who were treated with antidepressant medication, and who remained on medication for at least 180 days of a 231-day period following the earliest dispensing event.

**Numerator:** Patients in the denominator who remained on medication for at least 180 days of a 231-day period following the start of an antidepressant.

**Denominator:** Patients with at least one dispensing event for an antidepressant medication during the 12-month window starting on May 1 of the year prior to the measurement year and ending on April 30 of the measurement year, with a diagnosis of major depression within 60 days from the earliest dispensing event.
major depression within 60 days from the earliest dispensing event. This measure identifies patients with newly diagnosed depression who were started on an antidepressant, and who remained on medication for at least 180 days of a 231-day period following the start of an antidepressant.

Specialties:

*Family Practice,* General Practice,*Internal Medicine,*Psychiatry

Citations:


New bipolar disorder on antimanic agent (NQF) (2432)

Measure Description:

This measure identifies the percentage of patients with newly diagnosed bipolar disorder who have received at least 1 prescription for a mood-stabilizing agent during the measurement year.

Numerator: Patients in the denominator who have received at least 1 prescription for a mood-stabilizing agent during the measurement year.

Denominator: Patients newly diagnosed as having bipolar disorder earlier than 30 days before the end of the measurement year.

Specialties:

*Family Practice,* General Practice,*Internal Medicine,*Psychiatry

Citations:


HEDIS ADHD med follow-up visit within 30 days (3804)

Measure Description:

This measure identifies patients age 6 to 12 years with an ambulatory prescription dispensed for attention-deficit/hyperactivity disorder (ADHD) medication who had one follow-up visit during the 30-day initiation period.

Numerator: Patients from the denominator with one ambulatory follow-up visit within 30 days after the Index Prescription Start Date.

Denominator: Patients age 6 to 12 years as of the Index Prescription Episode Start Date who were dispensed an attention deficit/hyperactivity disorder (ADHD) medication during the 12-month Intake Period (Intake Period occurs before the last 8-months of the measurement year). Measure excludes patients with any claims history for narcolepsy or inpatient admissions for other mental health or substance abuse admissions.

Specialties:

*Family Practice,*General Practice,*Pediatrics,*Psychiatry

Citations:


HEDIS ADHD med follow-up visits within 9 months (3812)

Measure Description:

This measure identifies patients age 6 to 12 years with an ambulatory prescription dispensed for attention-deficit/hyperactivity disorder (ADHD) medication who had one follow-up visit during the 30-day initiation period and at least 2 follow-up visits with a practitioner within 270 days after the Initiation phase ended.

Numerator: Patients from the denominator with one ambulatory follow-up visit with a practitioner with prescribing authority within 30 days after the Index Prescription Start Date AND at least 2 follow-up visits (one may be via telephone) 31 to 300 days after the Index Start Date.
Denominator: Patients age 6 to 12 years as of the Index Prescription Start Date who were dispensed an ADHD medication during the 12-month Intake Period prior to the last 10 months of the measurement year, excluding patients with any claims history for narcolepsy.

Specialties:
*Family Practice,*General Practice,*Pediatrics,*Psychiatry

Citations:

Nephrology

Chronic kidney disease need annual lipid test (NQF) (11382)

Measure Description:
This measure identifies patients with chronic kidney disease who have been screened for dyslipidemia.

Numerator: Patients in the denominator who have had a lipid profile during the measurement year.

Denominator: Patients at least 12 years old who have been diagnosed with chronic kidney disease.

Specialties:
*Family Practice,*General Practice,*Internal Medicine,*Nephrology

Citations:
KDIGO guidelines for the evaluation and management of CKD address this rule somewhat. Found at: http://www.kdigo.org/clinical_practice_guidelines/ckd.php

Chronic kidney disease monitor calcium (NQF) (11378)

Measure Description:
This measure identifies patients with chronic kidney disease who are not on dialysis and have had the appropriate monitoring of their calcium level.

**Numerator:** Patients in the denominator who have had a calcium level test within 12 months after the date of chronic kidney disease diagnosis.

**Denominator:** Patients with chronic kidney disease without dialysis during the year prior to the measurement year.

**Specialties:**
- Family Practice
- General Practice
- Internal Medicine
- Nephrology

**Citations:**

---

**Chronic kidney disease monitor parathyroid hormone (11374)**

**Measure Description:**
This measure identifies patients with chronic kidney disease who are not on dialysis and have had the appropriate monitoring of their parathyroid hormone (PTH) level.

**Numerator:** Patients who have had a PTH level test within 12 months after the date of chronic kidney disease diagnosis.

**Denominator:** Patients with chronic kidney disease stages 4-5 without dialysis during the year prior to the measurement year who also do not have history of parathyroidectomy at any time prior to the diagnosis of chronic kidney disease.

**Specialties:**
- Family Practice
- General Practice
- Internal Medicine
- Nephrology

**Citations:**
KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD), Kidney...
Chronic kidney disease monitor phosphorus (NQF) (11379)

Measure Description:

This measure identifies patients with chronic kidney disease who are not on dialysis and have had the appropriate monitoring for their blood phosphorus level annually.

Numerator: Patients in the denominator who have had a phosphorus level test within 12 months after the date of chronic kidney disease diagnosis.

Denominator: Patients with chronic kidney disease without dialysis during the year prior to the measurement year.

Specialties:

*Family Practice,* General Practice,* Internal Medicine,* Nephrology

Citations:


Neurology

Migraine had prophylactic medication (NQF) (11401)

Measure Description:

This measure identifies patients with migraines who frequently take acute (abortive) medications who are on a prophylactic medication for migraine control.

Numerator: Patients in the denominator who have filled an anticonvulsant, beta-blocker, calcium channel blocker, or tricyclic antidepressant during the last 4 months of the measurement year and 3 months after the end of the measurement year).

Denominator: Patients 18 years or older diagnosed with migraine who are taking over 36 tablets of an oral triptan Rx, over 24 doses of subcutaneous triptan Rx, 24 spray bottles of nasal triptan Rx, 12.5ml of Butorphanol Tartrate, 12ml of Dihydroergotamine Mesylate, or 12 procedures for dihydroergotamine mesylate injections, 100 tablets of
butalbital containing medication, or 150 capsules of midrin type medication, over the last 4 months of the measurement year.

**Specialties:**

*Family Practice,* *General Practice,* *Internal Medicine,* *Neurology*

**Citations:**


**New dementia thyroid and B12 tests (2686)**

**Measure Description:**

This measure identifies the percentage of patients at least 50 years old newly diagnosed with dementia during the first 9 months of the measurement year who have received TSH and B12 testing from time of dementia diagnosis through the end of the measurement year.

**Numerator:** Patients in the denominator who have received TSH and B12 lab testing from time of dementia diagnosis through the end of the measurement year.

**Denominator:** Patients at least 50 years old newly diagnosed with dementia during the first 9 months of the measurement year.

**Specialties:**

*Family Practice,* *General Practice,* *Internal Medicine,* *Neurology*

**Citations:**


**Ophthalmology**

**Cataract surgery and no post-op complication (4393)**

**Measure Description:**

This measure identifies adult patients with a diagnosis of uncomplicated cataract who had cataract surgery during the measurement year and did not have any of a specified list of surgical procedures in the 30 days following cataract surgery, which would indicate the occurrence of any of the following major complications: retained nuclear fragments, endophthalmitis, dislocated or wrong power IOL, retinal detachment, or wound dehiscence.

**Specialties:**

*Ophthalmology*

**Citations:**


**Otolaryngology**

**Otitis media effusion no systemic antimicrobials (4396)**

**Measure Description:**

This measure identifies patients age 2 months through 12 years with a diagnosis of otitis media with effusion (OME) during the measurement year who were appropriately not prescribed systemic antimicrobials.

**Numerator:** Patients from the denominator who did not receive systemic antimicrobial therapy for OME.

**Denominator:** All patients age 2 months through 12 years with a diagnosis of OME during the measurement year.

**Specialties:**

*Family Practice,* General Practice,*Otolaryngology,* Pediatrics
Citations:


**Acute otitis externa avoid systemic antibiotics (4397)**

**Measure Description:**

This measure identifies patients age 2 years and older with a diagnosis of acute otitis externa (AOE) who were not prescribed systemic antimicrobial therapy within 7 days after the AOE episode.

**Numerator:** Patients from the denominator who did not receive systemic antimicrobial therapy within 7 days after the AOE episode.

**Denominator:** All patients age 2 years and older with a diagnosis of AOE during the measurement year.

**Specialties:**

*Family Practice,*General Practice,*Internal Medicine,*Otolaryngology,*Pediatrics

Citations:


**Tympanostomy tube hearing test (NQF) (4399)**

**Measure Description:**

This measure identifies patients age 2 months through 12 years with OME who received tympanostomy tube(s) insertion during the measurement year and had a hearing test performed 6 months prior to tube placement.

**Numerator:** Patients from the denominator who had their hearing tested at any time during the 6 month period preceding the tympanostomy procedure.
**Denominator:** Patients age 2 through 12 years old with OME who received tympanostomy tube(s) insertion during the measurement year.

**Specialties:**

*Family Practice,* *General Practice,* *Otolaryngology,* *Pediatrics*

**Citations:**


**Postoperative complications within one week of tonsillectomy (17912)**

**Measure Description:**

This measure identifies patients who had a tonsillectomy during the measurement year and did not experience intraoperative complications during the procedure or postoperative complications within one week of the procedure.

**Specialties:**

*Otolaryngology*

**Citations:**


**Postoperative complications within one week of septoplasty (17913)**

**Measure Description:**

This measure identifies patients who had a septoplasty during the measurement year and did not experience intraoperative complications during the procedure or postoperative complications within one week of the procedure.

**Specialties:**
*Otolaryngology

Citations:


Prenatal Care Measures

Pregnant woman needs Hepatitis B screening (NQF) (11387)

Measure Description:

This measure identifies women who had Hepatitis B screening during pregnancy.

Numerator: Individuals in the denominator who had Hepatitis B screening during the 280-day period prior to delivery.

Denominator: Women who were pregnant during the measurement year.

Specialties:

*Family Practice,*General Practice,*Internal Medicine,*Obstetrics & Gynecology

Citations:


Pregnant woman needs HIV screening (NQF) (11381)

Measure Description:

This measure identifies women who had a HIV test during pregnancy.

Numerator: Individuals in the denominator who had HIV testing during the 280-day period prior to delivery.

Denominator: Women who were pregnant during the measurement year.

Specialties:
*Family Practice,*General Practice,*Obstetrics & Gynecology

**Citations:**


**Pregnant woman needs syphilis screening (NQF) (11386)**

**Measure Description:**

This measure identifies women who had syphilis screening during pregnancy.

**Numerator:** Individuals in the denominator who had syphilis screening during the 280-day period prior to delivery.

**Denominator:** Women who were pregnant during the measurement year.

**Specialties:**

*Family Practice,*General Practice,*Internal Medicine,*Obstetrics & Gynecology

**Citations:**
CDC STD Screening guidelines, 2010:

http://www.ahrq.gov/clinic/uspstf/uspssyph.htm

**Preventive Health Measures: Women’s Health**

**High risk cervical cancer screening (NQF) (168)**

**Measure Description:**

This measure identifies women age 12 to 65 diagnosed with cervical dysplasia, cervical carcinoma-in-situ, or HIV/AIDS prior to the measurement year, and who still have a cervix, who had a cervical CA screen during the measurement year.

**Numerator:** Patients in the denominator who had a cervical CA screen during the measurement year.

**Denominator:** Women who are 12–65 years of age who have a diagnosis of cervical dysplasia, cervical carcinoma-in-situ, or HIV/AIDS diagnosed prior to the measurement year, and who still have a cervix (excludes women with a hysterectomy).

**Specialties:**

*Family Practice,*General Practice,*Internal Medicine,*Obstetrics & Gynecology,*Pediatrics,Gynecology

**Citations:**


**Cervical cancer screen 21-29 years of age (20542)**

**Measure Description:**

This rule identifies women between 21-29 years of age who received one or more Pap tests during the measurement year or the two years prior to the measurement year.
**Numerator:** Patients in the denominator who received one or more Pap tests during the measurement year or the two years prior to the measurement year.

**Denominator:** Women who are 24-29 years of age as of the end of the measurement year who have a cervix (excludes women with a hysterectomy).

**Specialties:**

*Family Practice,*General Practice,*Internal Medicine,*Obstetrics & Gynecology,Gynecology

**Citations:**


**Cervical cancer screen 30-64 years of age (183)**

**Measure Description:**

This rule identifies women between 30 and 64 years of age who had a cervical cancer screening during the measurement year or the two years prior to the measurement year or who had cervical cytology/HPV co-testing performed in the last 3 years.

**Numerator:** Patients in the denominator had a cervical cancer screening during the measurement year or the two years prior to the measurement year or who had cervical cytology/HPV co-testing performed in the last 3 years.

**Denominator:** Women who are 35-64 years of age as of the end of the measurement year who have a cervix (excludes women with a hysterectomy).

**Specialties:**

*Family Practice,*General Practice,*Internal Medicine,*Obstetrics & Gynecology,Gynecology

**Citations:**


**HEDIS chlamydia annual screening (384)**

**Measure Description:**
This measure identifies women age 16 to 24 identified as sexually active who had at least 1 Chlamydia test during the measurement year.

**Numerator:** Patients in the denominator who had 1 or more tests for Chlamydia during the measurement year.

**Denominator:** Females who are 16–24 years of age who were identified as sexually active (based on codes from claims during the measurement year that indicate pregnancy or abortion, as well as Rx claims for contraception).

**Specialties:**


**Citations:**


---

**HEDIS breast cancer screening in past 2 years (182)**

**Measure Description:**

This measure identifies women age 52 to 74 as of Dec 31st of the measurement year who had a mammogram during the measurement year or during the year prior to the measurement year.

**Numerator:** Patients in the denominator who had a mammogram during the measurement year or during year prior to the measurement year.

**Denominator:** Women who are 52-74 years of age by Dec 31st of the measurement year without evidence of history of breast cancer or a bilateral mastectomy.

**Specialties:**


**Citations:**

Preventive Health Measures: Well Child Visits

Age 0-1 year old appropriate office visits (5607)

Measure Description:

This measure identifies infants who have had at least 5 office visits during their first year of life.

Numerator: Patients in the denominator who have had => 5 office visits.

Denominator: Children who turn 1 year old during the measurement year.

Specialties:

*Family Practice,*General Practice,*Pediatrics

Citations:


Age 1-3 years old appropriate office visits (5608)

Measure Description:

This measure identifies children who turned 3 years old during the measurement year and had =>5 office visits from the age of 1 through 3.

Numerator: Patients in the denominator who have had => 5 office visits from the age of 1 through 3.

Denominator: Children who turn 3 years old during the measurement year.

Specialties:

*Family Practice,*General Practice,*Pediatrics

Citations:

Age 3-11 years old appropriate office visits (7842)

Measure Description:

This measure identifies children whose 4th through 11th birthdays occur during the measurement year who have \( \geq 1 \) office visit during the measurement year.

Numerator: Patients in the denominator who have had \( \geq 1 \) office visit during the measurement year.

Denominator: Children who are at least 3 years old and less than 11 years old at the start of the measurement year.

Specialties:

* Family Practice,* General Practice,* Pediatrics

Citations:


Age 12-18 years old appropriate office visits (7843)

Measure Description:

This measure identifies children whose 12th through 18th birthdays occur during the measurement year who have \( =1 \) office visit during the measurement year.

Numerator: Patients in the denominator who have had \( =1 \) office visit during the measurement year.

Denominator: Children who are at least 11 years old and less than 18 years old at the start of the measurement year.

Specialties:

* Family Practice,* General Practice,* Pediatrics

Citations:

**Pulmonary Measures: Asthma**

**Persistent asthma beta-2 agonist (228)**

**Measure Description:**

This measure identifies patients age 5 or older with persistent asthma present during the first 6 months of the measurement year who have filled a prescription for a short-term beta-2 agonist inhaler within the last 2 years.

**Numerator:** Patients in the denominator who received a short-term beta-2 agonist inhaler medication anytime during the measurement year or the year prior to the measurement year.

**Denominator:** Patients with persistent asthma activity (based on NCQA/HEDIS definition) during the first 6 months of the measurement year.

**Specialties:**

*Allergy & Immunology,*Family Practice,*General Practice,*Internal Medicine,*Pediatrics,*Pulmonary Disease,Pediatric Allergy,Pediatric Pulmonology

**Citations:**


**HEDIS persistent asthma appropriate med (2376)**

**Measure Description:**

This measure identifies the percentage of patients 5 to 64 years of age during the measurement year who were identified as having persistent asthma and who were appropriately prescribed medication during the measurement year.

**Specialties:**

*Allergy & Immunology,*Family Practice,*General Practice,*Internal Medicine,*Pediatrics,*Pulmonary Disease,Pediatric Allergy,Pediatric Pulmonology

**Citations:**
Asthma inappropriate ED use (17895)

Measure Description:

This measure identifies asthmatic patients who did not visit the Emergency Department (ER) for asthma related conditions during the measurement year.

Numerator: Patients in the denominator who did not visit the ER for asthma related conditions during the measurement year.

Denominator: Patients => 5 years of age who have asthma.

Specialties:


Citations:


Asthma spirometry to confirm diagnosis (17945)

Measure Description:

This measure identifies patients 11 years of age or older during the measurement year who have been newly diagnosed with asthma who received appropriate spirometry testing to confirm the diagnosis.

Numerator: Patients in the denominator who had a spirometry test either 2 years before or 6 months after the initial asthma diagnosis date.

Denominator: Patients 11 years of age or older as of December 31 of the measurement year with a new diagnosis of asthma during the 12 month period starting 6 months prior to the measurement year to the first 6 months of the measurement year.

Specialties:
Asthma needs periodic spirometry (17910)

Measure Description:

This measure identifies patients 10 years or older with a diagnosis of asthma at least two years ago who have had spirometry testing in the past two years.

Numerator: Patients in the denominator who had a spirometry test during the past two years.

Denominator: Patients turning 10 years of age or older during the measure year with asthma diagnosed at least two years ago.

Specialties:

*Family Practice,*General Practice,*Internal Medicine,*Pediatrics,*Pulmonary Disease,Pediatric Pulmonology

Citations:


Pulmonary Measures: COPD

COPD on long acting bronchodilator (NQF) (11397)

Measure Description:

This measure identifies members who have had a COPD exacerbation and who were prescribed a long-acting bronchodilator medication in the last 6 months.

Numerator: Patients in the denominator on a long-acting bronchodilator in the last 6 months of the measurement year.
**Denominator:** Patients 40 years or older with COPD exacerbations in the measurement year.

**Specialties:**
*Family Practice,* *General Practice,* *Internal Medicine,* *Pulmonary Disease*

**Citations:**

**COPD spirometry to confirm diagnosis (NQF) (10216)**

**Measure Description:**
This measure identifies patients age 40 or older who have been newly diagnosed with chronic obstructive pulmonary disease (COPD) who received appropriate spirometry testing to confirm the diagnosis.

**Numerator:** Patients in the denominator who had a spirometry test either 2 years before or 6 months after the initial COPD diagnosis date.

**Denominator:** Patients =$\geq$42 years old with a new diagnosis of COPD during the 12 month period starting 6 months prior to the measurement year to the first 6 months of the measurement year.

**Specialties:**
*Family Practice,* *General Practice,* *Internal Medicine,* *Pulmonary Disease*

**Citations:**


Asthma or COPD avoid beta-2 agonist overuse (225)

Measure Description:

This measure identifies patients with asthma or COPD who are not overusing beta-2 agonists.

Specialties:

*Family Practice,*General Practice,*Internal Medicine,*Pediatrics,*Pulmonary Disease,*Pediatric Pulmonology

Citations:


HEDIS COPD corticosteroid post discharge (6747)

Measure Description:

This measure is used to assess the percentage of chronic obstructive pulmonary disease (COPD) exacerbations for members 40 years of age and older who had an acute inpatient discharge or emergency department (ED) encounter between January 1 to December 1 of the measurement year and who were dispensed a systemic corticosteroid within 14 days of the event.

Numerator: Patients from the denominator who were dispensed a prescription for systemic corticosteroid on or 14 days after the COPD Episode Date.
**Denominator:** Patients 40 years of age or older as of January 1 of the measurement year with a COPD exacerbation as indicated by an acute inpatient discharge or emergency department (ED) encounter with a principal diagnosis of COPD.

**Specialties:**

*Family Practice,* General Practice,* Internal Medicine,* Pulmonary Disease

**Citations:**


**HEDIS COPD bronchodilator post discharge (7304)**

**Measure Description:**

This measure is used to assess the percentage of chronic obstructive pulmonary disease (COPD) exacerbations for members 40 years of age and older who had an acute inpatient discharge or emergency department (ED) encounter between January 1 to December 1 of the measurement year and who were dispensed a bronchodilator within 30 days of the event.

**Numerator:** Patients from the denominator who were dispensed a prescription for a bronchodilator on or 30 days after the COPD Episode Date. Bronchodilators as per NCQA/HEDIS: Anticholinergic agents (albuterol-ipratropium, ipratropium, tiotropium), Beta 2-agonists (albuterol, arformoterol, budesonide-formoterol, fluticasone-salmeterol, formoterol, levalbuterol, metaproterenol, pirbuterol, salmeterol), methylxanthines (dyphylline-guaifenesin, guaifenesin-theophylline, potassium iodide-theophylline)

**Denominator:** Patients 40 years of age or older as of January 1 of the measurement year with a COPD exacerbation as indicated by an acute inpatient discharge or emergency department (ED) encounter with a principal diagnosis of COPD.

**Specialties:**

*Family Practice,* General Practice,* Internal Medicine,* Pulmonary Disease

**Citations:**

COPD inappropriate ED use (17911)

Measure Description:

This measure identifies COPD patients who did not visit the Emergency Department (ER) for asthma related conditions during the measurement year.

Specialties:

*Family Practice,*General Practice,*Internal Medicine,*Pulmonary Disease

Citations:


Pulmonary Measures: Other Respiratory

HEDIS pharyngitis appropriate testing (385)

Measure Description:

This measure identifies children 2–18 years of age who were diagnosed with pharyngitis prior to or during the measurement year, dispensed an antibiotic, and had a test for group A streptococcus for the episode.

Numerator: Patients in the denominator who had a test for group A streptococcus (strep) for the episode of pharyngitis.

Denominator: Children age 2 to 18 who were diagnosed with pharyngitis and dispensed an antibiotic within 6 months prior to the measurement year or during the first 6 months of the measurement year.

Specialties:

*Family Practice,*General Practice,*Pediatrics

Citations:

HEDIS upper respiratory infection appropriate med (386)

**Measure Description:**

This measure identifies children age 3 months to 18 years who were diagnosed with an upper respiratory infection (URI) who did not receive an antibiotic prescription within 3 days after diagnosis.

**Numerator:** Patients in the denominator who did not receive an antibiotic prescription within 3 days after the diagnosis.

**Denominator:** Children age 3 months old as of 18 months prior to the end of the measurement year to 18 years old 6 months prior to the end of the measurement year who were diagnosed with URI between 545 and 180 days prior to the end of the measurement year.

**Specialties:**

*Family Practice,* General Practice,*Pediatrics

**Citations:**


HEDIS acute bronchitis avoid antibiotics (3817)

**Measure Description:**

This measure identifies adults age 18 to 64 years with a diagnosis of acute bronchitis who were not dispensed an antibiotic prescription on or within 3 days after the Index Episode Start Date.

**Numerator:** Patients from the denominator who were not dispensed a prescription for antibiotic medication on or within 3 days after the Index Episode Start Date.

**Denominator:** Patients =>18 years of age at the start of the year prior to the measurement year to =64 years of age by the end of the measurement year, with a Negative Medication History, a Negative Comorbid Condition History and a Negative Competing Diagnosis, who had an outpatient or emergency department (ED) visit with any diagnosis of acute bronchitis during the Intake Period.
Specialties:

*Family Practice,*General Practice,*Internal Medicine,*Pulmonary Disease

Citations:


**Rheumatology: Osteoporosis**

**Osteoporosis on pharmacological therapy (NQF) (11380)**

**Measure Description:**

This measure identifies osteoporosis patients who are on osteoporosis therapy.

**Numerator:** Patients in the denominator who have an osteoporosis therapy during the measurement year.

**Denominator:** Women 55 or older and men 50 or older who have been diagnosed with osteoporosis in the year prior to the measurement year.

Specialties:

*Family Practice,*General Practice,*Internal Medicine,*Rheumatology

Citations:


**Osteopenia and chronic steroids on osteoporosis Rx (NQF) (10226)**

**Measure Description:**

This measure identifies patients (females 55 years or older, or males 50 years or older) who have been diagnosed with osteopenia, are on a long-term steroid, and are on an appropriate osteoporosis therapy.

**Numerator:** Patients in the denominator who are on an osteoporosis therapy during the measurement year or have taken testosterone in the last 6 months of the measurement year.
**Denominator:** Female patients 55 years or older and male patients 50 years or older who have a diagnosis of osteopenia within the measurement year without history of osteoporosis and who have taken a steroid over the last 6 months of the measurement year.

**Specialties:**

*Family Practice,*General Practice,*Internal Medicine,*Obstetrics & Gynecology,*Rheumatology,Gynecology

**Citations:**


**Steroid use osteoporosis screening (NQF) (11390)**

**Measure Description:**

This measure identifies patients on chronic steroids for at least 6 months in the last 9 months of the measurement year who have had a bone density evaluation for osteoporosis screening.

**Numerator:** Patients in the denominator who have had a bone density evaluation or osteoporosis treatment in the measurement year.

**Denominator:** Patients over 18 years old who have been on chronic steroids for 6 out of the last 9 months of the measurement year.

**Specialties:**

*Family Practice,*General Practice,*Internal Medicine,*Rheumatology

**Citations:**

HEDIS osteoporosis management post fracture (389)

Measure Description:

This measure identifies women age 67 or older who suffered a bone fracture and had either a bone mineral density (BMD) test or a prescription for a drug to treat or prevent osteoporosis during the 6 months after the date of fracture.

Numerator: Patients in the denominator who had either a bone mineral density test or a prescription for a drug to treat or prevent osteoporosis in the 6 months after the date of fracture.

Denominator: Women who are 67 years or older who suffered a bone fracture during the 6 months prior to the measurement year or during the first 6 months of the measurement year.

Specialties:

*Family Practice,*General Practice,*Internal Medicine,*Obstetrics & Gynecology,*Orthopedic Surgery,*Rheumatology,Gynecology

Citations:


Rheumatology: Rheumatoid arthritis

HEDIS rheumatoid arthritis DMARD therapy (3794)

Measure Description:

This measure identifies patients with a diagnosis of RA and who were dispensed at least one ambulatory prescription for a disease-modifying anti-rheumatic drug (DMARD) during the measurement year.

Specialties:

*Family Practice,*General Practice,*Internal Medicine,*Rheumatology

Citations:

Rheumatoid Arthritis DMARD baseline CBC (NQF) (4311)

Measure Description:

This measure identifies adult patients with a diagnosis of rheumatoid arthritis who received appropriate baseline complete blood count (CBC) testing within 90 days before to 14 days after the new start of sulfasalazine, methotrexate, leflunomide, azathioprine, D-Penicillamine, intramuscular gold, oral gold, cyclosporine, or cyclophosphamide during the measurement year.

Numerator: Patients in the denominator who received CBC testing within 90 days before to 14 days after the new start of "DMARD needing baseline CBC.

Denominator: Patients =>18 years old with a history of rheumatoid arthritis and a new start of "DMARD needing baseline CBC (specifically, sulfasalazine, methotrexate, leflunomide, azathioprine, D-Penicillamine, intramuscular gold, oral gold, cyclosporine, or cyclophosphamide) during the measurement year.

Specialties:

*Family Practice,*General Practice,*Internal Medicine,*Rheumatology

Citations:


American College of Rheumatology's Starter Set of Measures for Quality in the Care for Rheumatic and Musculoskeletal Diseases, February 2006. American College of Rheumatology.


Rheumatoid arthritis DMARD baseline creatinine (NQF) (4361)

Measure Description:
This measure identifies adult patients with a diagnosis of rheumatoid arthritis who received appropriate baseline serum creatinine testing within 90 days before to 14 days after a new start of methotrexate, leflunomide, azathioprine, D-Penicillamine, intramuscular gold, cyclosporine, or cyclophosphamide during the measurement year.

Specialties:

*Family Practice,*General Practice,*Internal Medicine,*Rheumatology

Citations:


American College of Rheumatology's Starter Set of Measures for Quality in the Care for Rheumatic and Musculoskeletal Diseases, February 2006. American College of Rheumatology.


**Rheumatoid arthritis DMARD baseline AST or ALT (NQF) (4362)**

**Measure Description:**

This measure identifies adult patients with a diagnosis of rheumatoid arthritis who received appropriate baseline AST or ALT testing within 90 days before to 14 days after a new start of sulfasalazine, methotrexate, leflunomide, azathioprine, cyclosporine or cyclophosphamide during the measurement year.

**Numerator:** Patients in the denominator who received serum creatinine testing within 90 days before to 14 days after the new start of DMARD needing baseline AST or ALT.

**Denominator:** Patients =>18 years old with a history of rheumatoid arthritis and a new start of DMARD needing baseline AST or ALT (specifically, sulfasalazine, methotrexate, leflunomide, azathioprine, cyclosporine or cyclophosphamide) during the measurement year.

Specialties:

*Family Practice,*General Practice,*Internal Medicine,*Rheumatology

Citations:

American College of Rheumatology's Starter Set of Measures for Quality in the Care for Rheumatic and Musculoskeletal Diseases, February 2006. American College of Rheumatology.


**Rheumatoid arthritis hydroxychloroquine eye exam (NQF) (2426)**

**Measure Description:**

This measure identifies the percentage of patients with rheumatoid disease who received hydroxychloroquine during the measurement year and had a fundoscopic examination during the measurement year or in the year prior to the measurement year.

**Numerator:** Patients in the denominator who have undergone a fundoscopic exam by an eye care professional during the measurement year or in the year prior to the measurement year.

**Denominator:** Patients with a diagnosis of rheumatoid disease who were prescribed at least a 292-day supply of hydroxychloroquine during the measurement year, excluding those with a prior history of blindness.

**Specialties:**

*Family Practice,*General Practice,*Internal Medicine,*Ophthalmology,*Rheumatology

**Citations:**


Methotrexate 3 month CBC test (NQF) (2690)

Measure Description:

This measure identifies adult patients with rheumatoid arthritis who were prescribed at least a 6-month supply of methotrexate during the measurement year and who received a CBC test within 120 days (3 months + 1 month grace period) following the earliest observed methotrexate prescription claim.

Numerator: Patients in the denominator who received a CBC test in the 120 days following the earliest observed methotrexate prescription claim.

Denominator: Patients =>18 years old with rheumatoid arthritis who have received at least a 6-month supply of oral methotrexate during the measurement year.

Specialties:

*Family Practice,*General Practice,*Internal Medicine,*Rheumatology

Citations:


Methotrexate 3 month creatinine test (NQF) (2688)

Measure Description:

This measure identifies adult patients with rheumatoid arthritis who were prescribed at least a 6-month supply of methotrexate during the measurement year and received a serum creatinine test in the 120 days (3 months + 1 month grace period) after the earliest observed methotrexate prescription claim.

Numerator: Patients in the denominator who received a serum creatinine test in the 120 days following the earliest observed methotrexate prescription claim.

Denominator: Patients =>18 years old with rheumatoid arthritis who have received at least a 6-month supply of oral methotrexate during the measurement year.
Specialties:

*Family Practice,*General Practice,*Internal Medicine,*Rheumatology

Citations:


**Methotrexate 3 month liver function test (NQF) (2687)**

**Measure Description:**

This measure identifies adult patients with rheumatoid arthritis who were prescribed at least a 6-month supply of methotrexate during the measurement year and who received a liver function test in the 120 days (3 months + 1 month grace period) following the earliest observed methotrexate prescription claim.

**Numerator:** Patients in the denominator who received a liver function test in the 120 days following the earliest observed methotrexate prescription claim.

**Denominator:** Patients =>18 years old with rheumatoid arthritis who have received at least a 6-month supply of oral methotrexate during the measurement year.

**Specialties:**

*Family Practice,*General Practice,*Internal Medicine,*Rheumatology

**Citations:**
